PUT - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 13:55:07 2024-05-28 EDT | ||
| 3.15 EUR | +5.35% |
|
| Current month | -4.26% | ||
| 1 month | -8.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 3.15 | +5.35% |
| 24-05-27 | 2.99 | +5.65% |
| 24-05-24 | 2.83 | +2.17% |
| 24-05-23 | 2.77 | -7.97% |
| 24-05-22 | 3.01 | +2.38% |
Real-time Boerse Frankfurt Warrants
Last update May 28, 2024 at 01:55 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1XAV |
| ISIN | DE000VD1XAV5 |
| Date issued | 2024-03-08 |
| Strike | 1,150 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.4 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.2 € |
|---|---|
| Lowest since issue | 2.77 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
915.7
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- Certificat
